Indwelling Device-associated Biofilms (BiofilmICU)
Indwelling Device-associated Biofilms in Oncological Critically Ill Patients
Healthcare associated infections linked to the use of indwelling medical devices increase hospital morbidity, mortality and the Intensive Care treatment costs. The essential strategy for mitigating these consequences are prompt source identifcation and control, with appropriate antimicrobial therapy initiation as soon as possible. Removing the source is one of the golden rule for infection control. Early identification of the responsible germs is the other major guiding element for the appropriate anti-infectious treatment.
Despite multiple detection/identification methods, there are no clear recommendations for biofilm identification in clinical practice. The gold standard method is bacterial/fungal culturing, with disadvantages related to late results, especially for slow growing, fastidious germs or related to the existence of uncultivable strains.
In order to obtain more sensitive, specific results and to increase the chances of better biofilm characterization, in the present study the investigators compare biofilm identification results obtained by standard cultivation methods with those by DNA amplification and next generation gene sequencing. The studied biofilm is associated to four criticallly ill oncological patients indwelling devices (endotracheal tube, central venous catheter, arterial catheter and urinary catheter).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
According to Regional Institute of Oncology, Iasi protocols, all septic patients with the need of invasive ventilatory support (endotracheal intubation), have concomitantly inserted a CVC, an AC and a UC, as standard of care. All patients undergo the protocol for the management of suspected/proven sepsis: initial resuscitation, specimen collection for microbiology/molecular biology tests, empirical/targeted anti-infectious treatment, source control, multiple organ support and treatment of the underlying disease/comorbidities. All RIO patients are screened for nasal, pharyngeal and rectal pathogen colonization at the time of hospital/ICU admission.
Informed consent - During the first 24 hours of ICU admission, all eligible patients will receive written information about the study: its implementation, aims, expected advantages and possible risks, and they will be asked to sign an informed consent. If the patient is unable to give consent at ICU admission due to pathological or drug-induced acute alteration of consciousness, a legal representative may give authorization. Once the participant regains the decision capacity, the individual will be asked to confirm or withdraw consent.
Swab sampling - The nasal, pharyngeal and rectal screening swab sampling is collected according to standard methods. In addition to this standard screening, in the first 24 hours of ICU admission cutaneous samples from the groin area of enrolled patients will be obtained, with sterile Copan eSwabTM swabs, a product recommended for aerobic, anaerobic and fastidious microbial agents.
Biofilm sampling and transport - The extraction of the four ID (ET, CVC, AC, UC) will be performed when the clinical condition of the patient dictates it (suspected catheter infection/no further need due to improvement or death). These devices will be extracted by medical ICU personnel, only at the indication and according to the medical judgment of the clinician, without being influenced by the patient's study participation.
Microbiological processing and analysis of the biofilm - Microbiological analysis will be performed by standard method: sample seeding on standard culture media, then biochemical identification test and AST according to CLSI standards and guidelines using MicroScan Walk Away 40 plus®, Beckmann Coulter automatic system compatible pannels.
Molecular biology processing and analysis of the biofilm - After complete sample collection, gene sequencing of the variable regions V3-V4 16S rRNA gene will be performed using Illumina MiSeq® Next Generation Sequencer System.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Iasi, Romania, 7--483
- Regional Institute of Oncology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion criteria:
- Signed informed consent;
- Age ≥18 years;
- Suspected/proven sepsis/septic shock (Supplemental file 2);
- APACHE II score ≥10 (Supplemental file 3);
- Predictable invasive ventilatory support ≥ 48 hours;
- Patient estimated survival ≥ 4 days.
Exclusion criteria:
- Patient/legal representative refusal;
- Age <18 years;
- Chronic psychiatric/neurological disease with impaired decision-making capacity;
- Pregnancy;
- Invasive ventilatory support < 2 days;
- Death in less than 4 days after ICU admission.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The detection/identification of biofilm-associated pathogens
Lasso di tempo: through study completion, an average of 1 year
|
The detection/identification of biofilm-associated pathogens using Next Generation Sequencing (NGS) technique compared with standard microbiological diagnosis.
|
through study completion, an average of 1 year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Identification of pathogens involved in ID biofilm formation
Lasso di tempo: through study completion, an average of 1 year
|
Identification of pathogens involved in ID biofilm formation (ET, CVC, AC, UC) in the critically ill oncological patients.
|
through study completion, an average of 1 year
|
|
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples
Lasso di tempo: through study completion, an average of 1 year
|
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples (tracheal aspirate/bronchoalveolar lavage, blood culture, urinary culture, surgical wound swab, etc.) collected from the same patient.
|
through study completion, an average of 1 year
|
|
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples (tracheal aspirate/bronchoalveolar lavage, blood culture, urinary culture, surgical wound swab, etc.) collected from the same patient.
Lasso di tempo: through study completion, an average of 1 year
|
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples (tracheal aspirate/bronchoalveolar lavage, blood culture, urinary culture, surgical wound swab, etc.) collected from the same patient.
|
through study completion, an average of 1 year
|
|
Establishing clinico-biological correlations
Lasso di tempo: through study completion, an average of 1 year
|
Correlations between biofilm-associated pathogens and patient clinico-biological data:
|
through study completion, an average of 1 year
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Luminita Smaranda Iancu, Professor, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
- Direttore dello studio: Ioana Grigoras, Professor, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
- Direttore dello studio: Olivia Simona Dorneanu, Assoc Prof, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
- Direttore dello studio: Catalina Lunca, Assist Prof, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
- Cattedra di studio: Teodora Vremera, Assist Prof, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
- Cattedra di studio: Stefania Brandusa Copacianu, MD, PhD, Regional Institute of Oncology Iasi, Romania
- Cattedra di studio: Iuliu Ivanov, PhD, Regional Institute of Oncology Iasi, Romania
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- GTPopaUMPIASI
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .